[The efficacy of immunomodulating preparations in treating patients with chronic cholestatic liver diseases].

Radchenko VG, Mitrofanova TI, Serebriakova VI, Vinogradova GL

Likars'ka sprava1 Nov 1992

PMID1292217PepBankPUB-01292217

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymalin.

01HumanNot a test of Thymalin aloneNon-randomized trialEfficacy outcome
In chronic cholestatic liver disease, pooled levamisole, T + activin and thymalin treatment increased lymphocyte levels.
In plain wordsIn patients with chronic cholestatic liver disease, pooled treatments including thymalin increased lymphocyte levels.
Peptide
Thymalin
Outcome
IncreaseLymphocyte level
Study
n = 102
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
A study of 102 patients with chronic cholestatic liver diseases revealed that levamisole, T + activin and thymalin possess an immunostimulating effect increasing the level of lymphocytes, T-lymphocytes, activate the functional activity of lymphocytes in patients with chronic cholestatic hepatitis an…
In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.
Report a problemFND-0129221701
02HumanNot a test of Thymalin aloneNon-randomized trialEfficacy outcome
In chronic cholestatic liver disease, pooled levamisole, T + activin and thymalin treatment increased T-lymphocyte levels.
In plain wordsIn patients with chronic cholestatic liver disease, pooled treatments including thymalin increased T-lymphocyte levels.
Peptide
Thymalin
Outcome
IncreaseT-lymphocyte level
Study
n = 102
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
A study of 102 patients with chronic cholestatic liver diseases revealed that levamisole, T + activin and thymalin possess an immunostimulating effect increasing the level of lymphocytes, T-lymphocytes, activate the functional activity of lymphocytes in patients with chronic cholestatic hepatitis an…
In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.
Report a problemFND-0129221702
03HumanNot a test of Thymalin aloneNon-randomized trialEfficacy outcome
In chronic cholestatic hepatitis and primary biliary cirrhosis, pooled treatments including thymalin increased lymphocyte functional activity.
In plain wordsIn patients with these liver diseases, pooled treatments including thymalin increased lymphocyte activity.
Peptide
Thymalin
Outcome
IncreaseLymphocyte functional activity
Study
n = 102
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
A study of 102 patients with chronic cholestatic liver diseases revealed that levamisole, T + activin and thymalin possess an immunostimulating effect increasing the level of lymphocytes, T-lymphocytes, activate the functional activity of lymphocytes in patients with chronic cholestatic hepatitis an…
In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.
Report a problemFND-0129221703
04HumanNot a test of Thymalin aloneNon-randomized trialEfficacy outcome
In chronic cholestatic liver disease, pooled T = activin and thymalin treatment increased the contents of T-lymphocytes and their subpopulations.
In plain wordsIn patients with chronic cholestatic liver disease, pooled T = activin and thymalin treatment increased T-lymphocyte and subpopulation counts.
Peptide
Thymalin
Outcome
IncreaseT-lymphocyte and subpopulation content
Study
n: not reported in source
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
T = activin, thymalin produce a more pronounced normalization of the immune response by increasing the contents of T-lymphocytes and their subpopulations, elevating the functional activity of mononuclears, reducing the concentration of immunoglobulins, cyclic immune complexes.
In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.
Report a problemFND-0129221704
05HumanNot a test of Thymalin aloneNon-randomized trialEfficacy outcome
In chronic cholestatic liver disease, pooled T = activin and thymalin treatment increased mononuclear cell functional activity.
In plain wordsIn patients with chronic cholestatic liver disease, pooled T = activin and thymalin treatment increased mononuclear cell activity.
Peptide
Thymalin
Outcome
IncreaseMononuclear functional activity
Study
n: not reported in source
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
T = activin, thymalin produce a more pronounced normalization of the immune response by increasing the contents of T-lymphocytes and their subpopulations, elevating the functional activity of mononuclears, reducing the concentration of immunoglobulins, cyclic immune complexes.
In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.
Report a problemFND-0129221705
06HumanNot a test of Thymalin aloneNon-randomized trialEfficacy outcome
In chronic cholestatic liver disease, pooled T = activin and thymalin treatment reduced immunoglobulin concentration.
In plain wordsIn patients with chronic cholestatic liver disease, pooled T = activin and thymalin treatment reduced immunoglobulin concentration.
Peptide
Thymalin
Outcome
DecreaseImmunoglobulin concentration
Study
n: not reported in source
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
T = activin, thymalin produce a more pronounced normalization of the immune response by increasing the contents of T-lymphocytes and their subpopulations, elevating the functional activity of mononuclears, reducing the concentration of immunoglobulins, cyclic immune complexes.
In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.
Report a problemFND-0129221706
07HumanNot a test of Thymalin aloneNon-randomized trialEfficacy outcome
In chronic cholestatic liver disease, pooled T = activin and thymalin treatment reduced cyclic immune complex concentration.
In plain wordsIn patients with chronic cholestatic liver disease, pooled T = activin and thymalin treatment reduced cyclic immune complex concentration.
Peptide
Thymalin
Outcome
DecreaseCyclic immune complex concentration
Study
n: not reported in source
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
T = activin, thymalin produce a more pronounced normalization of the immune response by increasing the contents of T-lymphocytes and their subpopulations, elevating the functional activity of mononuclears, reducing the concentration of immunoglobulins, cyclic immune complexes.
In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.
Report a problemFND-0129221707

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.